gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Phase II study with bendamustin (flat dose) in patients with metastatic breast cancer

Meeting Abstract

  • corresponding author presenting/speaker Annette Frost - Klinik für Tumorbiologie, Freiburg, Deutschland
  • Simone Steinbild - Klinik für Tumorbiologie, Freiburg
  • Patrizia Siegert - Klinik für Tumorbiologie, Freiburg
  • Brigitte Häring - Klinik für Tumorbiologie, Freiburg
  • Renate Angerer - Klinik für Tumorbiologie, Freiburg
  • Clemens Unger - Klinik für Tumorbiologie, Freiburg
  • Klaus Mross - Klinik für Tumorbiologie, Freiburg

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPE096

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 20. März 2006

© 2006 Frost et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Introduction: Bendamustin is an alkylating agent with a unique characteristic. No cross-resistance to other alkylating agents is known, the drug has a broad spectrum of anticancer activity in lymphomas as well as in solid tumors. The objectives of the trial was to evaluate the antitumor activity and toxicity of a treatment with a flat dose of bendamustin in patients (pts) with advanced breast cancer (MBC) as 3rd or 4th line therapy.

Methods: Pts were treated with 200 mg bendamustin d1+2 q4wks (1 h infusion) until progressive disease or toxicity occurred. Pts with advanced or metastatic breast cancer who had received at least two or three different chemotherapy regimens were included in the trial. 22 patients were included. Mean age was 55 years (range: 31 to 78), mean body surface area was 1.8 m² (range: 1.5 to 2.2). 1 cycle was defined as a period of 4 weeks. Assessment of tumor size was performed before, after 2 cycles and after every 2 further cycles. Evaluation of toxicity was performed in regular time intervals and classified according CTC version 2.0.

Results: 4/22 dropped out due to noncompliance. 2/18 pts. had a partial response with 5 and 3 month time to progression, 6/18 pts. had a stable disease with 15+, 5, 4, 4, 3 and 2 month time to progression and 10/18 had PD. Grade 3 and 4 treatment-related toxicities were a rare event: leucopenia in 3/18; thrombocytopenia in 2/18; diarrhea in 2/18; nausea in 1/18; fatigue 1/18 and fever with infection in 3/18 pts. Grade 2 toxicities were more often seen: nausea in 4/18; weight loss in 5/18; fatigue in 6/18; anemia in 5/18 and leucopenia in 6/18 pts. The reatment-related toxicities were not correlated to body surface area or age.

Conclusion: Bendamustin had an acceptable toxicity profile and showed antitumor activity as 3rd and 4th line therapy in metastatic breast cancer patients. Cancer control (tumor regression and/or stable disease) is the main goal of a successful palliative anticancer therapy in far advanced MBC patients and was observed in 44%. A significant number of the evaluable patients had a beneficial tumor control for 4 month or more. A simple dosing system using flat dosages is recommended for palliative treatment protocols.